G1 Therapeutics, Inc. (GTHX) Net Income (Loss) Attributable to Parent USD 2016 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
G1 Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to 2024.
  • G1 Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$10.2 M, a 63% increase year-over-year.
  • G1 Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$30.6 M, a 75.7% increase year-over-year.
  • G1 Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$48 M, a 67.5% increase from 2022.
  • G1 Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$148 M, a 0.54% increase from 2021.
  • G1 Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$148 M, a 49.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$30.6 M -$10.2 M +$17.4 M +63% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-01
Q4 2023 -$48 M -$10.9 M +$22.8 M +67.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$70.7 M -$18.2 M +$7.07 M +28% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-01
Q2 2023 -$77.8 M $8.71 M +$48.2 M Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-01
Q1 2023 -$126 M -$27.6 M +$21.6 M +43.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-01
Q4 2022 -$148 M -$33.6 M +$6.37 M +15.9% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-01
Q3 2022 -$154 M -$25.3 M +$17.2 M +40.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-01
Q2 2022 -$171 M -$39.4 M -$24 K -0.06% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-01
Q1 2022 -$171 M -$49.2 M -$22.8 M -86% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-01
Q4 2021 -$148 M -$40 M -$14.7 M -57.9% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-01
Q3 2021 -$134 M -$42.5 M -$30.8 M -264% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-01
Q2 2021 -$103 M -$39.4 M -$8.21 M -26.3% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-01
Q1 2021 -$94.7 M -$26.4 M +$4.58 M +14.8% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-01
Q4 2020 -$99.3 M -$25.3 M +$10.1 M +28.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-23
Q3 2020 -$109 M -$11.7 M +$20.7 M +63.9% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-23
Q2 2020 -$130 M -$31.2 M -$520 K -1.69% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-23
Q1 2020 -$130 M -$31 M -$7.07 M -29.5% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-23
Q4 2019 -$122 M -$35.4 M -$11.3 M -47.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-24
Q3 2019 -$111 M -$32.4 M -$12.4 M -62.5% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-24
Q2 2019 -$98.7 M -$30.7 M -$9.82 M -47.1% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-24
Q1 2019 -$88.8 M -$24 M -$3.54 M -17.4% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-24
Q4 2018 -$85.3 M -$24.1 M -$7.11 M -41.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 -$78.2 M -$19.9 M -$4.32 M -27.7% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 -$73.9 M -$20.9 M -$5.67 M -37.3% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 -$68.2 M -$20.4 M -$8.07 M -65.3% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$60.1 M -$17 M -$6.58 M -63.3% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$53.5 M -$15.6 M -$9.04 M -138% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$44.5 M -$15.2 M -$7.82 M -106% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$36.7 M -$12.3 M -$6.39 M -107% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$30.3 M -$10.4 M Oct 1, 2016 Dec 31, 2016 10-K 2018-02-21
Q3 2016 -$6.56 M Jul 1, 2016 Sep 30, 2016 10-K 2018-02-21
Q2 2016 -$7.38 M Apr 1, 2016 Jun 30, 2016 10-K 2018-02-21
Q1 2016 -$5.95 M Jan 1, 2016 Mar 31, 2016 10-K 2018-02-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.